New drug aims to tame hepatitis b in HIV patients
NCT ID NCT05551273
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface antigen levels in the blood, which is a marker of the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selgantolimod (an oral drug that stimulates the immune system)
What this could lead to
If successful, this could point toward a way to lower hepatitis B virus levels in people who also have HIV, potentially reducing liver damage over time.
What could go wrong
This is a small, early-phase trial focused on safety and immune response, not a cure. The drug may not significantly reduce hepatitis B markers, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barranco CRS (Site 11301)
Lima, 04, Peru
-
Case CRS (Site ID# 2501)
Cleveland, Ohio, 44106, United States
-
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site 31784)
Chiang Mai, 50200, Thailand
-
Cincinnati Clinical Research Site (Site 2401)
Cincinnati, Ohio, 45267-0405, United States
-
Greensboro CRS (Site# 3203)
Greensboro, North Carolina, 27401, United States
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID# 12101)
Rio de Janeiro, 21040-360, Brazil
-
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site 12201)
Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site 31802)
Pathum Wan, Bangkok, 10330, Thailand
-
The Ponce de Leon Center CRS (Site 5802)
Atlanta, Georgia, 30308, United States
-
UCSD Antiviral Research Center CRS (Site 701)
San Diego, California, 92103, United States
-
Univ of Pittsburgh (Site 1001)
Pittsburgh, Pennsylvania, 15213, United States
-
Weill Cornell Chelsea CRS (Site 7804)
New York, New York, 10011, United States